A Randomized, Parallel-group, Open, Two-period, Comparative Non-inferiority Study of Eurofarma's Formoterol/budesonide Vs Alenia in the Treatment of Moderate to Severe Persistent Asthma with and Without Chronic Obstructive Pulmonary COPD
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ESPIRE
- Sponsors Eurofarma
Most Recent Events
- 14 Feb 2025 Status changed from recruiting to completed.
- 16 May 2024 Planned End Date changed from 30 Jul 2025 to 30 Nov 2025.
- 16 May 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Mar 2025.